2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T43a,A total of 506 patients received 683 treatments: acitretin (n = 316), methotrexate (n = 245) and cyclosporine (n = 122). Median drug survival at 2 years was similar for acitretin (10.8 months) and methotrexate (10.9 months), but lower for cyclosporine (3.9 months; p < 0.0001). The most common reasons for discontinuation were inefficacy for cyclosporine (43.0%), and loss of effectiveness for acitretin (27.2%) and methotrexate (31.8%). No demographic, clinical or therapeutic characteristics were associated with higher rates of treatment maintenance at 6 months. Drug survival was higher for acitretin when used as a first-line therapy (median drug survival: 11.3 months for first-line vs. 5.5 months for second- or subsequent-line therapy; p < 0.001), but there were no differences for methotrexate and cyclosporine. Adverse events (AEs) were the reason for stopping treatment in 13.8% of patients on acitretin, 23.1% on methotrexate and 14.0% on cyclosporine (p = 0.02). Only one serious AE was reported: hepatitis in the methotrexate group.31:Tdc4,Three conventional systemic treatments, acitretin, methotrexate and cyclosporine, are used for severe childhood psoriasis. In many countries, they are the only treatments available. There are limited data and no comparative evaluations of these treatments. The international, multicentre, retrospective, real-world ACMe cohort was developed to assess the comparative 2-year drug survival of acitretin, methotrexate and cyclosporine in paediatric psoriasis. Thirty dermatology centres in France, Italy, Portugal, Canada and the United Kingdom participated in the study. Demographic and clinical data were collected using a standardized form for patients receiving treatment from 2014 to 2024. A total of 506 patients received 683 treatments: acitretin (n = 316), methotrexate (n = 245) and cyclosporine (n = 122). Median drug survival at 2 years was similar for acitretin (10.8 months) and methotrexate (10.9 months), but lower for cyclosporine (3.9 months; p < 0.0001). The most common reasons for discontinuation were inefficacy for cyclosporine (43.0%), and loss of effectiveness for acitretin (27.2%) and methotrexate (31.8%). No demographic, clinical or therapeutic characteristics were associated with higher rates of treatment maintenance at 6 months. Drug survival was higher for acitretin when used as a first-line therapy (median drug survival: 11.3 months for first-line vs. 5.5 months for second- or subsequent-line therapy; p < 0.001), but there were no differences for methotrexate and cyclosporine. Adverse events (AEs) were the reason for stopping treatment in 13.8% of patients on acitretin, 23.1% on methotrexate and 14.0% on cyclosporine (p = 0.02). Only one serious AE was reported: hepatitis in the methotrexate group. This cohort study showed that acitretin and methotrexate had comparable 2-year drug survival rates, which were superior to cyclosporine. We did not find any predictive factors for increased treatment maintenance except for first-line use of acitretin. AEs were a frequent reason for discontinuing treatments. These results may help develop treatment algorithms for systemic therapy in paediatric psoriasis. Severe forms of psoriasis may require the use of general treatments. Three usual treatments (acitretin, methotrexate and cyclosporine) are used for severe childhood psoriasis. In many countries, they are the only treatments available. In this international, multicentre, retrospective study, we compared the 2‐year drug survival (duration before stopping treatment) of these treatments in paediatric psoriasis. Thirty dermatology centres from five countries included 506 patients who received 683 treatments: acitretin (n = 316), methotrexate (n = 245) and cyclosporine (n = 122). Median drug survival at 2 years was similar for acitretin and methotrexate, but lower for cyclosporine. The most common reasons for discontinuation were inefficacy for cyclosporine and loss of effectiveness for acitretin and methotrexate. We did not identify demographic, clinical or therapeutic characteristics associated with higher rates of treatment maintenance at 6 months. Adverse events were the reason for stopping treatment in 13.8% of patients on acitretin, 23.1% on methotrexate and 14.0% on cyclosporine. This study showed that acitretin and methotrexate had comparable 2‐year drug survival rates, which were superior to cyclosporine. These results may help develop treatment algorithms for systemic therapy in pediatric psoriasis.32:Tb7c,AbstractBackgroundThree conventional systemic treatments, acitretin, methotrexate and cyclosporine, are used for severe childhood psoriasis. In many countries, they are the only treatments available. There are limited data and no comparative evaluations of these treatments.ObjectivesThe international, multicentre, retrospective, real‐world ACMe cohort was developed to assess the comparative 2‐year drug survival of acitretin, methotrexate and cyclosporine in paediatric psoriasis.MethodsThirty dermatology centres in France, Italy, Portugal, Canada and the United Kingdom participated in the study. Demographic and clinical data were collected using a standardized form for patients receiving treatment from 2014 to 2024.ResultsA total of 506 patients received 683 treatments: acitretin (n = 316), methotrexate (n = 245) and cyclosporine (n = 122). Median drug survival at 2 years was similar for acitretin (10.8 months) and methotrexate (10.9 months), but lower for cyclosporine (3.9 months; p < 0.0001). The most common reasons for discontinuation were inefficacy for cyclosporine (43.0%), and loss of effectiveness for acitretin (27.2%) and methotrexate (31.8%). No demographic, clinical or therapeutic characteristics were associated with higher rates of treatment maintenance at 6 months. Drug survival was higher for acitretin when used as a first‐line therapy (median drug survival: 11.3 months for first‐line vs. 5.5 months for second‐ or subsequent‐line therapy; p < 0.001), but there were no differences for methotrexate and cyclosporine. Adverse events (AEs) were the reason for stopping treatment in 13.8% of patients on acitretin, 23.1% on methotrexate and 14.0% on cyclosporine (p = 0.02). Only one serious AE was reported: hepatitis in the methotrexate group.ConclusionsThis cohort study showed that acitretin and methotrexate had comparable 2‐year drug survival rates, which were superior to cyclosporine. We did not find any predictive factors for increased treatment maintenance except for first‐line use of acitretin. AEs were a frequent reason for discontinuing treatments. These results may help develop treatment algorithms for systemic therapy in paediatric psoriasis.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"acitretin: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on acitretin (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/acitretin\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"acitretin\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/acitretin\"}]}}"}}]],["$","$L2f",null,{"title":"acitretin: Research & Clinical Takeaways","description":"Explore research on acitretin (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0662","pmid":"42549604","title":"Combination Therapy with Upadacitinib and Acitretin in Recalcitrant Darier Disease: A Case Report","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-08-04T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0662","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-10T13:22:12.462Z","updated_at":"2026-08-10T13:22:12.462Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"brand","value":"Rinvoq","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"condition","value":"Darier Disease","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"generic","value":"acitretin","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"warning","value":"A concurrent 2026 case report (Sun Z, Bao L) also describes upadacitinib monotherapy for DD with the same ATP2A2 p.N767S mutation — the present case claims to be the first combination therapy report, not the first upadacitinib report overall.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"warning","value":"Single patient (n=1); results should not be generalized without larger controlled studies.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0662","tag_type":"warning","value":"The brand name 'Rinvoq' was inferred for upadacitinib and is not explicitly stated in the paper.","value_numeric":null}],"summaries":{"what_studied":"A 29-year-old male with a 10-year history of refractory Darier disease (DD), previously partially responsive to acitretin 30 mg/day, was treated with upadacitinib 15 mg/day combined with acitretin 20 mg/day for 6 months, with acitretin tapered off at month 6.","key_result":"By month 1, pruritus dropped from VAS 8/10 to 2/10; by month 3, near-complete resolution (VAS 0/10, mDDI 3, DLQI 4 vs. baseline mDDI 12, DLQI 18); at month 6, sustained remission on upadacitinib monotherapy with no adverse events or lab abnormalities.","limitations":"Single-case design limits generalizability; short follow-up (6 months) precludes conclusions about long-term safety or durability of remission; no controlled comparison to other JAK inhibitor regimens.","practice_takeaway":"For patients with refractory DD failing oral retinoids, upadacitinib 15 mg/day combined with low-dose acitretin may achieve rapid control within 1 month, with the potential to taper and discontinue the retinoid thereafter. This dual-pathway approach warrants consideration as a retinoid-sparing strategy, pending larger studies."}},{"doi":"10.1111/pde.70313","pmid":"42409581","title":"Can Systemic Treatment for Childhood Psoriasis Be Stopped in Cases of Remission? Data From the\n ACMe\n Cohort","journal_title":"Pediatric Dermatology","journal_issn":"0736-8046","published_at":"2026-07-06T00:00:00.000Z","url":"https://doi.org/10.1111/pde.70313","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-14T13:24:12.952Z","updated_at":"2026-07-14T13:24:12.952Z","tags":[{"paper_doi":"10.1111/pde.70313","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"generic","value":"acitretin","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"generic","value":"cyclosporine","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"modality","value":"Antimetabolite","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"modality","value":"Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"sample_size","value":"n=433","value_numeric":433},{"paper_doi":"10.1111/pde.70313","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"warning","value":"Follow-up was limited to 6 months; durability of remission beyond this window is unknown and authors explicitly call for longer-term prospective studies.","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"warning","value":"Sex distribution of the study population is not reported in the abstract; the 'mixed' sex tag is assumed.","value_numeric":null},{"paper_doi":"10.1111/pde.70313","tag_type":"warning","value":"The 'impact_flag' of practice_changing was applied cautiously — results are promising but come from a retrospective design without long-term data.","value_numeric":null}],"summaries":{"what_studied":"This retrospective, multicenter, international real-world cohort study (ACMe) evaluated whether systemic therapy (acitretin, methotrexate, or cyclosporine) could be safely stopped in pediatric patients with moderate-to-severe psoriasis who achieved remission, and sought predictors of sustained remission over 6 months.","key_result":"Of 433 patients analyzed, 79 (18.2%) stopped systemic treatment due to remission; 70 of those 79 (88.6%) remained off systemic therapy for at least 6 months. Predictors of achieving remission-driven discontinuation included younger age (9.0 vs. 10.5 years, p<0.001), lower baseline PASI (9.3 vs. 11.1, p<0.04), lower PGA (3.0 vs. 3.3, p<0.04), and non-palmoplantar psoriasis (6.3% vs. 16.4%, p=0.02). No predictors of sustained remission at 6 months were identified.","limitations":"- Retrospective design limits causal inference and may introduce selection bias.\n- Follow-up capped at 6 months — longer-term relapse rates are unknown.\n- No predictors of *sustained* remission were found, limiting patient selection guidance.","practice_takeaway":"In pediatric patients with moderate-to-severe psoriasis who reach remission on conventional systemics, stopping treatment appears feasible — nearly 9 in 10 stayed off systemic therapy for 6 months. Younger children and those with lower baseline severity or non-palmoplantar disease are most likely to achieve remission-driven discontinuation."}},{"doi":"10.1053/j.ajkd.2026.01.011","pmid":"42167833","title":"Malignancy and Kidney Transplant: Core Curriculum 2026","journal_title":"American Journal of Kidney Diseases","journal_issn":"0272-6386","published_at":"2026-05-20T00:00:00.000Z","url":"https://doi.org/10.1053/j.ajkd.2026.01.011","source_score":24,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-03T13:44:31.911Z","updated_at":"2026-06-03T13:44:31.911Z","tags":[{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"brand","value":"Opdivo","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"AL Amyloidosis","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"Cutaneous Squamous Cell Carcinoma","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"Kidney Transplantation","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"Melanoma","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"Merkel Cell Carcinoma","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"Multiple Myeloma","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"Plasma Cell Dyscrasia","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"Posttransplant Lymphoproliferative Disorder","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"condition","value":"Renal Cell Carcinoma","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"acitretin","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"belzutifan","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"cemiplimab","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"daratumumab","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"ipilimumab","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"lenalidomide","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"mycophenolate mofetil","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"sirolimus","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"generic","value":"tacrolimus","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"modality","value":"Anti-CD38 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"modality","value":"Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"modality","value":"CAR-T Cell Therapy","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"modality","value":"mTOR Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"modality","value":"Oncolytic Virus Therapy","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"modality","value":"Proteasome Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"modality","value":"Tyrosine Kinase Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"study_design","value":"Review Article / Core Curriculum","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"warning","value":"Emerging therapies (oncolytic virus, EBV-VST, CAR-T in transplant) are discussed based on early-phase or limited case data and should not be considered standard of care.","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"warning","value":"ICI rejection risk figures (25–42%) are pooled from retrospective cohorts with heterogeneous IS reduction practices, limiting direct applicability.","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"warning","value":"Sample size tag omitted as no single study population is defined across this multi-topic review.","value_numeric":null},{"paper_doi":"10.1053/j.ajkd.2026.01.011","tag_type":"warning","value":"This is a narrative Core Curriculum review, not a primary research study; evidence grades vary widely by topic and most recommendations are expert consensus or based on observational data.","value_numeric":null}],"summaries":{"what_studied":"This Core Curriculum reviews cancer risk, screening, and management in kidney transplant candidates and recipients (KTRs), covering skin cancers, PTLD, plasma cell dyscrasias, and solid tumors, with emphasis on immunosuppression (IS) management and emerging therapies including immune checkpoint inhibitors (ICIs) and CAR-T cells.","key_result":"KTRs face 2–4× higher overall cancer risk vs. the general population; skin cancer SIRs reach 65–250 (cSCC) and 13–24 (Merkel cell); DLBCL is 8× more common; kidney cancer is 7× more common. ICI use carries ~25–42% acute rejection risk; patients on corticosteroids + mTOR inhibitors had lower rejection (HR 0.30). Median overall survival after transplant was 8.4 years for myeloma and 8.6 years for AL amyloidosis KTRs.","limitations":"Most recommendations are based on expert consensus, observational data, and case series rather than RCTs; ICI safety/efficacy data in KTRs come largely from retrospective analyses; screening benefit on long-term mortality in KTRs remains unproven.","practice_takeaway":"Convert azathioprine to mycophenolate or switch to an mTOR inhibitor for KTRs with recurrent non-melanoma skin cancers; minimize IS (remove antimetabolites first) when initiating ICI, and treat ICI-associated rejection with pulse steroids rather than antithymocyte globulin to preserve antitumor response. Cervical cancer screening should be more frequent (every 6–12 months) after transplant, and IMiDs should be stopped ≥4 weeks before kidney transplant in myeloma patients."}},{"doi":"10.1007/s13555-026-01761-7","pmid":"42068460","title":"A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-05-02T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01761-7","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-10T13:20:36.620Z","updated_at":"2026-05-10T13:20:36.620Z","tags":[{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Enbrel","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Otezla","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Sotyktu","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"acitretin","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"apremilast","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"cyclosporine","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"deucravacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"roflumilast","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"Conventional Synthetic DMARD","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"NSAID","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"PDE4 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"TYK2 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Corresponding author (Tsen-Fang Tsai) has disclosed extensive consultant relationships with manufacturers of many drugs discussed in the review.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Level of evidence assigned as 5 (narrative review/expert opinion) due to absence of PRISMA methodology, risk-of-bias tools, or meta-analytic synthesis, even though individual cited studies range from Level 1 to Level 5.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Several drug-AD associations cited are from studies in rheumatoid arthritis populations, not specifically psoriasis patients; generalizability to psoriatic disease may be limited.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"This is a narrative review without formal systematic methods; findings are hypothesis-generating and subject to selection bias in included studies.","value_numeric":null}],"summaries":{"what_studied":"This narrative review examined whether systemic drugs used for psoriatic disease (NSAIDs, methotrexate, cyclosporin, retinoids, PDE4 inhibitors, JAK inhibitors, TYK2 inhibitors, and biologics targeting TNF-α, IL-12/23, IL-17, and IL-23) influence the risk or progression of Alzheimer's disease (AD), using AD as a model for dementia. Literature from PubMed (2015–2025) was synthesized across preclinical, observational, and RCT-level evidence.","key_result":"Most preclinical and observational data suggest antipsoriatic therapies may reduce AD risk. The strongest clinical signal comes from a propensity score–matched cohort (n=1,766) showing biologic therapy for psoriasis was associated with a **53% lower risk of incident dementia** vs. conventional systemic therapy alone. In a large EHR-based study (56 million records), TNF inhibitors (etanercept, adalimumab, infliximab) were linked to markedly reduced AD odds (ORs 0.34, 0.28, and 0.52, respectively; all P<0.0001). However, several large observational studies found the psoriasis–dementia association attenuated or disappeared after adjusting for comorbidities.","limitations":"- Narrative (not systematic) review with no PRISMA flow, risk-of-bias assessment, or quantitative synthesis, limiting reproducibility.\n- Most mechanistic evidence comes from preclinical models (Level 5), with very few adequately powered RCTs in humans.\n- Residual confounding by disease severity, metabolic comorbidities, and medication use cannot be excluded in observational studies.","practice_takeaway":"For older patients with psoriasis, consider early cognitive screening, as shared inflammatory mechanisms may raise dementia risk—especially in those with metabolic comorbidities. Biologic therapy, particularly TNF inhibitors, shows the most consistent signal for possible neuroprotection, but current evidence is hypothesis-generating and should not yet change prescribing solely for dementia prevention."}},{"doi":"10.1111/jdv.70108","pmid":"41104794","title":"Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study","journal_title":"Journal of the European Academy of Dermatology and Venereology","journal_issn":"0926-9959","published_at":"2025-10-17T00:00:00.000Z","url":"https://doi.org/10.1111/jdv.70108","source_score":15,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-22","doi":"10.1111/jdv.70108","days":"14","issn":"0926-9959","rank":"9","field":"Clinical Medicine","score":"15","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jdv.70108","title":"Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","methods":"","results":"$30","abstract":"$31","keywords":["acitretin","cyclosporine","methotrexate","paediatric","psoriasis","psoriatic arthritis"],"pubmed_id":"41104794","conclusions":"","publication_date":"2025-10-17T00:00:00"},"crossref":{"DOI":"10.1111/jdv.70108","URL":"https://doi.org/10.1111/jdv.70108","ISSN":["0926-9959","1468-3083"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.70108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study"],"author":[{"given":"Yunyun","family":"Miao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hôpital Victor Dupouy Groupement Hospitalier de Territoire Sud Val d'Oise ‐ Nord Hauts‐de‐Seine Argenteuil France"}]},{"given":"Alain","family":"Beauchet","sequence":"additional","affiliation":[{"name":"Department of Public Health Centre Hospitalier Universitaire Raymond Poincaré, Assistance Publique‐Hôpitaux de Paris Garches France"}]},{"given":"Maryam","family":"Piram","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics, CHU Sainte‐Justine Research Center Université de Montréal Montréal Quebec Canada"}]},{"given":"Tess","family":"McPherson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oxford University Hospitals NHS Trust Oxford UK"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centro Académico Clínico, ICBAS/Santo António University of Porto Porto Portugal"}]},{"given":"Yasmine","family":"Yesli","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics, CHU Sainte‐Justine Research Center Université de Montréal Montréal Quebec Canada"}]},{"given":"Hélène","family":"Aubert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hôtel‐Dieu Centre Hospitalier Universitaire de Nantes Nantes France"}]},{"given":"Christine","family":"Bodemer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dermatology, Centre Hospitalier Universitaire Necker‐Enfants Malades Assistance Publique‐Hôpitaux de Paris Paris France"}]},{"given":"Cristina","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Arcispedale Santa Maria Nuova Azienda USL‐IRCCS di Reggio Emilia Reggio Emilia Italy"}]},{"given":"Mathilde","family":"Tardieu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dermatology Centre Hospitalier Universitaire Grenoble Alpes Grenoble France"}]},{"given":"Thomas","family":"Hubiche","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hôpital Archet 2 Nice France"}]},{"given":"Bertille","family":"Bonniaud","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Hôpital Le Bocage Centre Hospitalier Régional Universitaire de Dijon Dijon France"}]},{"given":"Iria","family":"Neri","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCSS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy"}]},{"given":"Marco Adriano","family":"Chessa","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCSS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy"}]},{"given":"Audrey","family":"Lasek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hôpital Saint Vincent de Paul Université Catholique de Lille Lille France"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[{"name":"Dermatology Section, Department of Health Science University of Florence Florence Italy"}]},{"given":"Sébastien","family":"Barbarot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hôtel‐Dieu Centre Hospitalier Universitaire de Nantes Nantes France"}]},{"given":"Anne‐Claire","family":"Bursztejn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centre Hospitalier Régional Universitaire de Nancy Hôpitaux de Brabois Vandœuvre‐lès‐Nancy France"}]},{"given":"Sophie","family":"Leducq","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Unit of Pediatric Dermatology University of Tours and Nantes, INSERM 1246 SPHERE, Centre Hospitalier Régional Universitaire de Tours Tours France"}]},{"given":"Margaux","family":"Sergeant","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centre Hospitalier Régional Universitaire de Nancy Hôpitaux de Brabois Vandœuvre‐lès‐Nancy France"}]},{"given":"Eve","family":"Puzenat","sequence":"additional","affiliation":[{"name":"Department of Dermatology Centre Hospitalier Régional Universitaire de Besançon Besançon France"}]},{"given":"Christine","family":"Chiaverini","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hôpital Archet 2 Nice France"}]},{"given":"Nina","family":"Sigg","sequence":"additional","affiliation":[{"name":"Department of Dermatology Centre Hospitalier Universitaire d'Angers Angers France"}]},{"given":"Stéphanie","family":"Mallet","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centre Hospitalier Universitaire de la Timone Hôpitaux Universitaires de Marseille – Assistance Publique‐Hôpitaux de Marseille Marseille France"}]},{"given":"Juliette","family":"Miquel","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology Centre Hospitalier Universitaire de St‐Pierre Saint‐Pierre La Réunion France"}]},{"given":"Diane","family":"Pourchot","sequence":"additional","affiliation":[{"name":"Department of Dermatology Centre Hospitalier Poissy‐Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France"}]},{"given":"Kinari Xina","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dermatology, St John's Institute of Dermatology Guy's and St Thomas' NHS Foundation Trust London UK"}]},{"given":"Esther","family":"Burden‐Teh","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine University of Nottingham Nottingham UK"}]},{"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dermatology, St John's Institute of Dermatology Guy's and St Thomas' NHS Foundation Trust London UK"}]},{"given":"Vito","family":"Di Lernia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Arcispedale Santa Maria Nuova Azienda USL‐IRCCS di Reggio Emilia Reggio Emilia Italy"}]},{"given":"Emmanuel","family":"Mahé","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hôpital Victor Dupouy Groupement Hospitalier de Territoire Sud Val d'Oise ‐ Nord Hauts‐de‐Seine Argenteuil France"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,10,17]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-17T12:09:42Z","timestamp":1760702982000,"date-parts":[[2025,10,17]]},"indexed":{"date-time":"2025-10-17T12:41:21Z","timestamp":1760704881624,"date-parts":[[2025,10,17]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000,"date-parts":[[2025,10,17]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.70108"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2024-12-16"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-15"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-17"}],"deposited":{"date-time":"2025-10-17T12:09:46Z","timestamp":1760702986000,"date-parts":[[2025,10,17]]},"issn-type":[{"type":"print","value":"0926-9959"},{"type":"electronic","value":"1468-3083"}],"published":{"date-parts":[[2025,10,17]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/j.1365-2133.2009.09593.x","key":"e_1_2_13_2_1","year":"2010","issue":null,"author":"Augustin M","volume":"162","first-page":"633","unstructured":null,"article-title":"Epidemiology and comorbidity of psoriasis in children","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2009.07.029","key":"e_1_2_13_3_1","year":"2010","issue":null,"author":"Tollefson MM","volume":"62","first-page":"979","unstructured":null,"article-title":"Incidence of psoriasis in children: a population‐based study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.14507","key":"e_1_2_13_4_1","year":"2016","issue":null,"author":"Burden‐Teh E","volume":"174","first-page":"1242","unstructured":null,"article-title":"The epidemiology of childhood psoriasis: a scoping review","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2013.1078","key":"e_1_2_13_5_1","year":"2013","issue":null,"author":"Paller AS","volume":"149","first-page":"166","unstructured":null,"article-title":"Association of pediatric psoriasis severity with excess and central adiposity: an international cross‐sectional study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.13507","key":"e_1_2_13_6_1","year":"2015","issue":null,"author":"Mahé E","volume":"172","first-page":"1593","unstructured":null,"article-title":"Psoriasis and obesity in French children: a case‐control, multicentre study","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.08.049","key":"e_1_2_13_7_1","year":"2020","issue":null,"author":"Menter A","volume":"82","first-page":"161","unstructured":null,"article-title":"Joint American Academy of Dermatology‐National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/17512433.2021.1911641","key":"e_1_2_13_8_1","year":"2021","issue":null,"author":"Mahé E","volume":"14","first-page":"807","unstructured":null,"article-title":"Perspectives on the pharmacological management of psoriasis in pediatric and adolescent patients","journal-title":"Expert Rev Clin Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40272-015-0137-1","key":"e_1_2_13_9_1","year":"2015","issue":null,"author":"Bronckers IM","volume":"17","first-page":"373","unstructured":null,"article-title":"Psoriasis in children and adolescents: diagnosis, management and comorbidities","journal-title":"Paediatr Drugs","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.annder.2020.01.021","key":"e_1_2_13_10_1","year":"2020","issue":null,"author":"Mahé E","volume":"147","first-page":"429","unstructured":null,"article-title":"Prescriptions hors AMM (autorisation de mise sur le marché) dans le psoriasis de l'enfant","journal-title":"Ann Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/ddg.13936","key":"e_1_2_13_11_1","year":"2019","issue":null,"author":"Eisert L","volume":"17","first-page":"959","unstructured":null,"article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents ‐ short version part 2","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-022-00758-2","key":"e_1_2_13_12_1","year":"2022","issue":null,"author":"Peris K","volume":"12","first-page":"1753","unstructured":null,"article-title":"Update on the Management of Pediatric Psoriasis: an Italian consensus","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2019.4835","key":"e_1_2_13_13_1","year":"2020","issue":null,"author":"Bronckers IMGJ","volume":"156","first-page":"384","unstructured":null,"article-title":"A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/pde.12940","key":"e_1_2_13_14_1","year":"2016","issue":null,"author":"Di Lernia V","volume":"33","first-page":"530","unstructured":null,"article-title":"Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis","journal-title":"Pediatr Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.2340/actadv.v102.1000","key":"e_1_2_13_15_1","year":"2022","issue":null,"author":"Bruins FM","volume":"102","first-page":"adv00745","unstructured":null,"article-title":"Real‐world methotrexate use in a prospective cohort of Paediatric patients with plaque psoriasis: effectiveness, adverse events and folic acid regimen","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.3109/09546634.2015.1088131","key":"e_1_2_13_16_1","year":"2016","issue":null,"author":"Van Geel MJ","volume":"27","first-page":"214","unstructured":null,"article-title":"Fumaric acid esters in recalcitrant pediatric psoriasis: a prospective, daily clinical practice case series","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.13713","key":"e_1_2_13_17_1","year":"2017","issue":null,"author":"Ergun T","volume":"44","first-page":"630","unstructured":null,"article-title":"Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2017.3029","key":"e_1_2_13_18_1","year":"2017","issue":null,"author":"Bronckers IMGJ","volume":"153","first-page":"1147","unstructured":null,"article-title":"Safety of systemic agents for the treatment of pediatric psoriasis","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.320.7244.1240","key":"e_1_2_13_19_1","year":"2000","issue":null,"author":"Cole TJ","volume":"320","first-page":"1240","unstructured":null,"article-title":"Establishing a standard definition for child overweight and obesity worldwide: international survey","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.2340/00015555-2625","key":"e_1_2_13_20_1","year":"2017","issue":null,"author":"Mahé E","volume":"97","first-page":"632","unstructured":null,"article-title":"Socioeconomic inequalities and severity of plaque psoriasis at a first consultation in dermatology centers","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.annder.2019.03.007","key":"e_1_2_13_21_1","year":"2019","issue":null,"author":"Lavaud J","volume":"146","first-page":"771","unstructured":null,"article-title":"Scores de sévérité dans le psoriasis de l'enfant: revue systématique de la littérature","journal-title":"Ann Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.3109/09546634.2014.996515","key":"e_1_2_13_22_1","year":"2015","issue":null,"author":"Geel MJV","volume":"26","first-page":"406","unstructured":null,"article-title":"Methotrexate in pediatric plaque‐type psoriasis: long‐term daily clinical practice results from the child‐CAPTURE registry","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.adengl.2013.01.001","key":"e_1_2_13_23_1","year":"2013","issue":null,"author":"Carretero G","volume":"104","first-page":"598","unstructured":null,"article-title":"Guidelines for the use of acitretin in psoriasis","journal-title":"Actas Dermo‐Sifiliográficas (English Edition)","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_13_24_1","year":"2001","issue":null,"author":"Mahé E","volume":"137","first-page":"1532","unstructured":null,"article-title":"Cyclosporine in childhood psoriasis","journal-title":"Arch Dermatol","doi-asserted-by":null},{"DOI":"10.3109/09546634.2015.1120852","key":"e_1_2_13_25_1","year":"2016","issue":null,"author":"Di Lernia V","volume":"27","first-page":"395","unstructured":null,"article-title":"Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41584-024-01079-8","key":"e_1_2_13_26_1","year":"2024","issue":null,"author":"Shenoi S","volume":"20","first-page":"170","unstructured":null,"article-title":"Treatment of non‐systemic juvenile idiopathic arthritis","journal-title":"Nat Rev Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1002/pds.3763","key":"e_1_2_13_27_1","year":"2015","issue":null,"author":"Raguideau F","volume":"24","first-page":"526","unstructured":null,"article-title":"Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.14326","key":"e_1_2_13_28_1","year":"2016","issue":null,"author":"Charbit L","volume":"174","first-page":"1118","unstructured":null,"article-title":"Systemic treatments in childhood psoriasis: a French multicentre study on 154 children","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/pde.15327","key":"e_1_2_13_29_1","year":"2023","issue":null,"author":"Siegfried EC","volume":"40","first-page":"789","unstructured":null,"article-title":"Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines","journal-title":"Pediatr Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_13_30_1","year":"2020","issue":null,"author":"Mahé E","volume":"10","first-page":"45","unstructured":null,"article-title":"Optimal management of plaque psoriasis in adolescents: current perspectives","journal-title":"Psoriasis (Auckl)","doi-asserted-by":null},{"DOI":"10.1016/j.annder.2019.07.005","key":"e_1_2_13_31_1","year":"2020","issue":null,"author":"Lavaud J","volume":"147","first-page":"29","unstructured":null,"article-title":"Proactive treatment in childhood psoriasis","journal-title":"Ann Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1093/bjd/ljac128","key":"e_1_2_13_32_1","year":"2023","issue":null,"author":"Maul JT","volume":"188","first-page":"533","unstructured":null,"article-title":"Access to psoriasis treatment in Brazil and Chile: a cross‐sectional multicentre global healthcare study on psoriasis","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jdv.70108"],"article-number":"jdv.70108","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"reference-count":31,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,17]]},"references-count":31,"short-container-title":["Acad Dermatol Venereol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jdv.70108","is_oa":false,"title":"Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study","updated":"2025-10-18T00:09:12+00:00","published_date":"2025-10-17","best_oa_location":null}},"created_at":"2025-10-27T13:37:43.000Z","updated_at":"2025-11-03T07:01:44.169Z","tags":[{"paper_doi":"10.1111/jdv.70108","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"generic","value":"acitretin","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"generic","value":"cyclosporine","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"modality","value":"Antimetabolite","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"modality","value":"Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"modality","value":"Systemic Retinoid","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"sample_size","value":"n=506","value_numeric":506},{"paper_doi":"10.1111/jdv.70108","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"warning","value":"Handling of repeated treatments per patient is not described in the abstract.","value_numeric":null},{"paper_doi":"10.1111/jdv.70108","tag_type":"warning","value":"The abstract reports medians (months) rather than 2‑year survival probabilities.","value_numeric":null}],"summaries":{"what_studied":"International, multicentre, retrospective cohort comparing 2‑year drug survival of acitretin, methotrexate, and cyclosporine for paediatric psoriasis across 30 centres in five countries (2014–2024); 506 children received 683 treatment courses.","key_result":"Median drug survival was 10.8 months for acitretin and 10.9 months for methotrexate, versus 3.9 months for cyclosporine (p<0.0001). Acitretin had longer survival when used first line (11.3 vs 5.5 months; p<0.001).","limitations":"Retrospective, non-randomized design. The abstract does not detail how multiple treatment courses per patient (683 courses in 506 patients) were handled analytically.","practice_takeaway":"Expect shorter persistence with cyclosporine than with acitretin or methotrexate over 2 years; only acitretin showed better persistence when started first line. Adverse events prompted discontinuation in 13.8% (acitretin), 23.1% (methotrexate), and 14.0% (cyclosporine), with one serious event (hepatitis) on methotrexate."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"acitretin"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"acitretin"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"acitretin"}}}]]

Papers